Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Programmed death-ligand 1 expression in patients with primary or secondary myelofibrosis.

Cancer reports (Hoboken, N.J.) - 1 Sept 2024

Ibrahim Moayed, Murphree Catherine, Patel Kirtesh, Mastrodomenico Matthew, Saba Nakhle S, Safah Hana, Schmid Janet, Socola Francisco

Abstract excerpt

BACKGROUND: It has been described in mice models that myeloproliferative neoplasm (MPN) with JAK2-V617F mutation has an increased expression of programmed death-ligand 1 (PD-L1) in megakaryocytes leading to cancer immune evasion by inhibiting the T-lymphocytes. AIMS: To quantify and compare the PD-L1 expression on bone marrow (BM) of patients with MPN JAK2 positive, negative, and normal controls. METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Bone Marrow

Share to Case-Control Studies

Share to Janus Kinase 2

Share to Megakaryocytes

Share to Primary Myelofibrosis

Source

Open in PubMed Open full text

Identifiers

PMID: 39233645
DOI: 10.1002/cnr2.2054
PMCID: PMC11375330

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Programmed death-ligand 1 expression in patients with primary or secondary myelofibrosis.PMID 39233645Read ↗

Programmed Death-Ligand 1 (PD-L1) Expression in Patients with Primary or Secondary MyelofibrosisSemantic proximity Read ↗

Cellular expression of PD-1, PD-L1 and CTLA-4 in patients with JAK2V617F mutated myeloproliferative disorders.Semantic proximity Read ↗

Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.Semantic proximity Read ↗

PD-L1 and JAK2 mRNA level in essential thrombocythaemia depends on the driver mutational status and the bone marrow fibrosis gradeSemantic proximity Read ↗

Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.Semantic proximity Read ↗

Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.Semantic proximity Read ↗

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signalingSemantic proximity Read ↗

Quantitative assessment of innate myeloid cells in myelofibrosis: insights into myeloid and plasmacytoid dendritic cell depletion and disease progression.Semantic proximity Read ↗

miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient plateletsSemantic proximity Read ↗

Effects of Ruxolitinib on Immune Checkpoint Molecule Expression in JAK2 V617F-Positive Cells.Semantic proximity Read ↗

High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 MutationsSemantic proximity Read ↗

Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.